Gufic BioSciences Ltd

Gufic BioSciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Nov 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 21 January 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Gufic BioSciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Gufic BioSciences Ltd has experienced a notable shift in price momentum, with technical indicators signalling a bearish trend across multiple timeframes. The company’s shares have declined by 2.88% today, reflecting growing investor caution amid deteriorating technical signals and a downgrade in its Mojo Grade to Strong Sell.

Gufic BioSciences Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its technical momentum, with several indicators signalling a bearish trend. Despite a modest weekly price gain, the stock’s overall technical profile has deteriorated, prompting a downgrade to a Strong Sell rating by MarketsMOJO as of 17 Nov 2025.

Gufic BioSciences Ltd has experienced a notable shift in its technical momentum, reflecting a complex interplay of mildly bearish and bullish signals across key indicators. Despite a modest daily price increase of 0.93%, the stock remains under pressure with a Strong Sell mojo grade, underscoring ongoing challenges in the Pharmaceuticals & Biotechnology sector.

Gufic BioSciences Ltd has experienced a marked deterioration in its technical outlook, with key momentum indicators signalling a shift towards bearishness. The stock’s recent price action, combined with weakening moving averages and mixed momentum oscillators, underscores mounting challenges for investors amid a broader sectoral and market context.

Gufic BioSciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 December 2025, providing investors with the latest insights into its performance and outlook.

Gufic BioSciences, a player in the Pharmaceuticals & Biotechnology sector, is currently exhibiting a shift in price momentum as reflected by recent technical indicator changes. The stock’s performance over various time frames contrasts notably with benchmark indices, while key technical signals suggest a prevailing bearish trend in the near term.

Gufic BioScience has experienced a revision in its market evaluation reflecting shifts in its financial and technical outlook. The pharmaceutical and biotechnology company’s recent assessment highlights a complex interplay of valuation concerns, financial performance, and market sentiment, underscoring the challenges faced by this small-cap stock in a competitive sector.

Gufic BioSciences, a notable player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of market forces and indicator signals. Recent evaluation adjustments reveal a transition in price trends and technical parameters, offering investors a detailed landscape of the stock’s current positioning amid broader market dynamics.

Gufic BioSciences has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across key indicators. The stock’s recent price movements and technical parameters suggest a cautious outlook amid broader sector and market dynamics.

Gufic BioSciences has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across key indicators. The stock’s recent price movements and technical parameters suggest a cautious market stance amid broader sector dynamics and fluctuating investor sentiment.

Gufic BioScience, a small-cap player in the Pharmaceuticals & Biotechnology sector, has undergone a revision in its market evaluation reflecting recent shifts in its financial and technical outlook. This adjustment follows a period marked by subdued profitability and valuation concerns, impacting investor sentiment and stock performance.

Gufic BioSciences, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a nuanced market assessment. Recent price movements and technical indicators suggest a transition from a predominantly bearish stance to a more mildly bearish outlook, underscoring evolving investor sentiment and market dynamics.

Gufic BioSciences Ltd., a Mumbai-based pharmaceutical manufacturer with a market capitalisation of ₹3,199 crores, reported a challenging quarter ended September 2025, with net profit declining 22.74% year-on-year to ₹16.82 crores despite posting its highest-ever quarterly revenue. The stock has tumbled 29.82% over the past year, significantly underperforming both the Sensex and the broader pharmaceuticals sector, reflecting investor concerns over deteriorating profitability metrics and mounting interest costs.